A 26-week neonate is started on total parenteral nutrition (TPN). The composition includes amino acids 3 g/kg/day, dextrose 10 g/kg/day, lipid emulsion 2 g/kg/day. On day 5, the baby develops conjugated hyperbilirubinemia (direct bilirubin 2.8 mg/dL), elevated ALT, and acholic stools. Which intervention has the best evidence to prevent progression of parenteral nutrition-associated liver disease (PNALD)?
- A Switch lipid emulsion from soy-based Intralipid to fish oil-based (Omegaven) or mixed lipid emulsion (SMOFlipid) ✓
- B Add ursodeoxycholic acid to the TPN
- C Reduce total caloric intake by 20%
- D Discontinue lipid emulsion immediately
Explanation
Parenteral nutrition-associated liver disease (PNALD / IFALD) is a major complication of prolonged TPN in preterm neonates, particularly related to soy-based lipid emulsions (Intralipid) which contain high phytosterols that impair bile acid homeostasis. Multiple clinical studies show that switching to fish oil-based lipid emulsions (Omegaven) or multi-oil emulsions (SMOFlipid, which contains a mix of soy, MCT, olive oil, and fish oil) reduces conjugated bilirubin levels and prevents progression to liver failure. Enteral feeds, even minimal enteral nutrition, also reduce PNALD by stimulating bile flow. Ursodeoxycholic acid has limited evidence. Fish oil emulsions are now standard in many NICUs for at-risk infants.
Reference: Ghai Essential Pediatrics, 10th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.